Punctal Plug Drug Delivery System (PPDS)
Building upon a well-known ocular device – punctal plugs – our objective is to complete the development of PPDS as a proprietary, minimally invasive drug delivery system that can be used to introduce a variety of therapeutic agents to the eye through controlled, sustained release to the tear film.
Placed in the tear duct, or punctum, of the eye in a simple office procedure routinely performed by an ophthalmologist or optometrist, punctal plugs have been traditionally used to block the drainage of tears in patients with dry eye syndrome and the dry eye effects of various ocular surface diseases.
Our platform technology will comprise a proprietary punctal plug designed to be retained for the desired treatment duration and a proprietary drug delivery core that can be tailored to deliver a wide range of therapeutic agents over different time periods. We're currently targeting the treatment of glaucoma and ocular hypertension, and intend to examine opportunities for delivery of steroidal and non-steroidal anti-inflammatories. Other areas of potential interest include therapeutic agents for dry eye syndrome as well as ocular allergies.